PDE6D Inhibitors
PDE6D, also known as phosphodiesterase 6D, plays a crucial role in intracellular signaling pathways, particularly in regulating cyclic nucleotide levels. Specifically, PDE6D is a key component of the phototransduction cascade in rod and cone photoreceptor cells of the retina. In this context, its primary function is to hydrolyze cyclic guanosine monophosphate (cGMP), thereby contributing to the termination of the light response and the restoration of the dark state in photoreceptor cells. By modulating cGMP levels, PDE6D helps to regulate ion channel activity and neurotransmitter release, ultimately influencing visual signal transduction and retinal function.
Inhibition of PDE6D activity can disrupt the normal physiological processes in photoreceptor cells, leading to impaired vision and contributes to retinal diseases such as retinitis pigmentosa and age-related macular degeneration. Mechanistically, inhibition of PDE6D can result in elevated levels of cGMP within photoreceptor cells, leading to sustained activation of cGMP-gated ion channels and aberrant signaling. This dysregulation can disrupt the delicate balance of ion fluxes across the cell membrane, impairing neurotransmitter release and synaptic transmission. Additionally, prolonged elevation of cGMP levels can lead to cellular stress and dysfunction, contributing to photoreceptor degeneration and vision loss. Therefore, targeting PDE6D inhibition may represent a strategy for retinal diseases, aimed at restoring normal cyclic nucleotide signaling and preserving visual function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits PDE6D by selectively targeting phosphodiesterase 4 (PDE4), which indirectly affects PDE6D activity. By inhibiting PDE4, Rolipram increases intracellular cAMP levels, impacting the cAMP signaling cascade where PDE6D participates. This indirect inhibition involves Rolipram modulating the cAMP-dependent pathways associated with PDE6D, influencing downstream cellular processes. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX) inhibits PDE6D by acting as a non-selective inhibitor of cyclic nucleotide phosphodiesterases. IBMX directly modulates PDE6D by preventing the degradation of cAMP and cGMP. This direct inhibition involves IBMX competitively inhibiting PDE6D, leading to altered cyclic nucleotide signaling and downstream effects on cellular processes where PDE6D is implicated. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole inhibits PDE6D by blocking adenosine uptake, leading to increased extracellular adenosine levels. This indirect inhibition involves Dipyridamole impacting the adenosine signaling pathway, influencing the cellular processes where PDE6D is involved. By modulating adenosine levels, Dipyridamole indirectly influences PDE6D activity and downstream effects on cellular processes. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits PDE6D by selectively targeting cyclic GMP-specific phosphodiesterases. This direct inhibition involves Zaprinast competitively inhibiting PDE6D, preventing the degradation of cGMP. By modulating cyclic GMP signaling, Zaprinast directly influences PDE6D activity and downstream effects on cellular processes where PDE6D is implicated. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide inhibits PDE6D by selectively targeting cyclic AMP-specific phosphodiesterases. This direct inhibition involves Cilostamide competitively inhibiting PDE6D, preventing the degradation of cAMP. By modulating cyclic AMP signaling, Cilostamide directly influences PDE6D activity and downstream effects on cellular processes where PDE6D is implicated. | ||||||
Piclamilast | 144035-83-6 | sc-478653 | 5 mg | $300.00 | ||
Piclamilast inhibits PDE6D by selectively targeting phosphodiesterase 4 (PDE4), which indirectly affects PDE6D activity. By inhibiting PDE4, Piclamilast increases intracellular cAMP levels, impacting the cAMP signaling cascade where PDE6D participates. This indirect inhibition involves Piclamilast modulating the cAMP-dependent pathways associated with PDE6D, influencing downstream cellular processes. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine inhibits PDE6D by acting as a non-selective phosphodiesterase inhibitor. This direct inhibition involves Caffeine preventing the degradation of cAMP and cGMP by inhibiting multiple phosphodiesterases, including PDE6D. By modulating cyclic nucleotide signaling, Caffeine directly influences PDE6D activity and downstream effects on cellular processes where PDE6D is implicated. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine inhibits PDE6D by selectively targeting phosphodiesterase 1 (PDE1). This direct inhibition involves Vinpocetine competitively inhibiting PDE6D, preventing the degradation of cAMP and cGMP. By modulating cyclic nucleotide signaling, Vinpocetine directly influences PDE6D activity and downstream effects on cellular processes where PDE6D is implicated. | ||||||
Papaverine | 58-74-2 | sc-279951 sc-279951A sc-279951B | 10 mg 50 mg 100 mg | $153.00 $265.00 $459.00 | ||
Papaverine inhibits PDE6D by selectively targeting phosphodiesterase 10 (PDE10). This direct inhibition involves Papaverine competitively inhibiting PDE6D, preventing the degradation of cAMP and cGMP. By modulating cyclic nucleotide signaling, Papaverine directly influences PDE6D activity and downstream effects on cellular processes where PDE6D is implicated. | ||||||
Anagrelide hydrochloride | 58579-51-4 | sc-203513 sc-203513A | 10 mg 50 mg | $103.00 $587.00 | 1 | |
Anagrelide inhibits PDE6D by selectively targeting phosphodiesterase 3 (PDE3). This direct inhibition involves Anagrelide competitively inhibiting PDE6D, preventing the degradation of cAMP and cGMP. By modulating cyclic nucleotide signaling, Anagrelide directly influences PDE6D activity and downstream effects on cellular processes where PDE6D is implicated. | ||||||